BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Follow-Up Questions
Qui est le CEO de BeOne Medicines AG ?
Mr. John Oyler est le Co-Founder de BeOne Medicines AG, il a rejoint l'entreprise depuis 2010.
Quelle est la performance du prix de l'action ONC ?
Le prix actuel de ONC est de $336.24, il a decreased de 1.93% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de BeOne Medicines AG ?
BeOne Medicines AG appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de BeOne Medicines AG ?
La capitalisation boursière actuelle de BeOne Medicines AG est de $34.0B
Est-ce que BeOne Medicines AG est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour BeOne Medicines AG, y compris 2 achat fort, 11 achat, 1 maintien, 0 vente et 2 vente forte
